TORONTO, July 18,
2022 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or
the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a global leader in medical
cannabis throughout Latin America
and Europe, today announced that
Helen Bellwood (ACA) will be
appointed as Interim CFO, replacing Swapan
Kakumanu of RTB LLP, effective immediately.
Prior to her appointment as Interim CFO, Ms. Bellwood was acting
as Head of Finance for Khiron´s European operations, based in
London (United Kingdom). Ms. Bellwood currently heads
the Company's Finance Department in Europe since 2021 and has been working for
Zerenia™ Clinics UK since its inception. Over the time, Ms.
Bellwood has gained an in-depth understanding of this industry and
the Company. Ms. Bellwood is a Chartered Accountant ACA (ICAEW),
and has more than 24 years of experience in finance, including five
years as an auditor for KPMG in the UK and has served as a senior
global finance executive for various British-based CPG companies,
such as Diageo PLC and Majestic Wine PLC.
Mr. Alvaro Torres, Khiron CEO and
Director, commented: "On behalf of the Board of Directors and the
management team, I would like to thank Swapan and RTB for their
contributions to our finance team, and we welcome Helen to this new
interim CFO role. Having worked closely with Helen, we have full
confidence in her experience, financial leadership, and business
acumen to assume this important role at Khiron, as we continue to
grow our operations in Europe and
Latin America. The UK has become
and continues to be more significant to Khiron´s overall revenue
and profitability, with more than 1 million
CAD in revenue just in the first quarter of this year, and a
clear path towards short-term EBITDA positivity".
About Khiron Life Sciences
Corp.
Khiron is a leading vertically integrated international medical
cannabis corporation with core operations in Latin America and Europe. Leveraging medical health clinics and
proprietary telemedicine platforms, Khiron combines a
patient-oriented approach, physician education programs,
scientific, product innovation, and cannabis operations expertise
to drive prescriptions and brand loyalty with patients worldwide.
The Company has a sales presence in Colombia, Peru, Germany, United
Kingdom, and Brazil and is
positioned to commence sales in Mexico. The Company is led by co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced and diverse executive
team and Board of Directors.
Visit Khiron online at https://investors.khiron.ca.
Linkedin
https://www.linkedin.com/company/khiron-life-sciences-corp/
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Cautionary Statement Regarding
Forward-Looking Statements
This press release may contain "forward-looking information"
within the meaning of applicable securities legislation. All
information contained herein that is not historical in nature
constitutes forward-looking information. Forward-looking
information and statements contained herein reflect management's
current beliefs and is based on information currently available and
on assumptions that management believes to be reasonable. These
assumptions include, but are not limited to, assumptions regarding
the future regulatory developments and economic conditions, the
Company's ability to continue its growth and reduce costs. The
Company undertakes no obligation to update or revise any
forward-looking information, whether as a result of new
information, estimates or opinions, future events or results or
otherwise or to explain any material difference between subsequent
actual events and such forward-looking information, except as
required by applicable law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-appoints-helen-bellwood-aca-as-interim-cfo-301587740.html
SOURCE Khiron Life Sciences Corp.